Literature DB >> 17060456

Activation of p53-dependent growth suppression in human cells by mutations in PTEN or PIK3CA.

Jung-Sik Kim1, Carolyn Lee, Challice L Bonifant, Habtom Ressom, Todd Waldman.   

Abstract

In an effort to identify genes whose expression is regulated by activated phosphatidylinositol 3-kinase (PI3K) signaling, we performed microarray analysis and subsequent quantitative reverse transcription-PCR on an isogenic set of PTEN gene-targeted human cancer cells. Numerous p53 effectors were upregulated following PTEN deletion, including p21, GDF15, PIG3, NOXA, and PLK2. Stable depletion of p53 led to reversion of the gene expression program. Western blots revealed that p53 was stabilized in HCT116 PTEN(-/-) cells via an Akt1-dependent and p14(ARF)-independent mechanism. Stable depletion of PTEN in untransformed human fibroblasts and epithelial cells also led to upregulation of p53 and senescence-like growth arrest. Simultaneous depletion of p53 rescued this phenotype, enabling PTEN-depleted cells to continue proliferating. Next, we tested whether oncogenic PIK3CA, like inactivated PTEN, could activate p53. Retroviral expression of oncogenic human PIK3CA in MCF10A cells led to activation of p53 and upregulation of p53-regulated genes. Stable depletion of p53 reversed these PIK3CA-induced expression changes and synergized with oncogenic PIK3CA in inducing anchorage-independent growth. Finally, targeted deletion of an endogenous allele of oncogenic, but not wild-type, PIK3CA in a human cancer cell line led to a reduction in p53 levels and a decrease in the expression of p53-regulated genes. These studies demonstrate that activation of PI3K signaling by mutations in PTEN or PIK3CA can lead to activation of p53-mediated growth suppression in human cells, indicating that p53 can function as a brake on phosphatidylinositol (3,4,5)-triphosphate-induced mitogenesis during human cancer pathogenesis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17060456      PMCID: PMC1800819          DOI: 10.1128/MCB.00537-06

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  55 in total

1.  Facile methods for generating human somatic cell gene knockouts using recombinant adeno-associated viruses.

Authors:  Manu Kohli; Carlo Rago; Christoph Lengauer; Kenneth W Kinzler; Bert Vogelstein
Journal:  Nucleic Acids Res       Date:  2004-01-02       Impact factor: 16.971

2.  The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate.

Authors:  T Maehama; J E Dixon
Journal:  J Biol Chem       Date:  1998-05-29       Impact factor: 5.157

3.  PTEN tumor suppressor regulates p53 protein levels and activity through phosphatase-dependent and -independent mechanisms.

Authors:  Daniel J Freeman; Andrew G Li; Gang Wei; Heng-Hong Li; Nathalie Kertesz; Ralf Lesche; Andrew D Whale; Hilda Martinez-Diaz; Nora Rozengurt; Robert D Cardiff; Xuan Liu; Hong Wu
Journal:  Cancer Cell       Date:  2003-02       Impact factor: 31.743

4.  Frequent somatic mutations in PTEN and TP53 are mutually exclusive in the stroma of breast carcinomas.

Authors:  Keisuke Kurose; Kristie Gilley; Satoshi Matsumoto; Peter H Watson; Xiao-Ping Zhou; Charis Eng
Journal:  Nat Genet       Date:  2002-10-15       Impact factor: 38.330

5.  Stable suppression of tumorigenicity by virus-mediated RNA interference.

Authors:  Thijn R Brummelkamp; René Bernards; Reuven Agami
Journal:  Cancer Cell       Date:  2002-09       Impact factor: 31.743

6.  Delta Np63 alpha expression is regulated by the phosphoinositide 3-kinase pathway.

Authors:  Christopher E Barbieri; Christopher E Barton; Jennifer A Pietenpol
Journal:  J Biol Chem       Date:  2003-10-10       Impact factor: 5.157

7.  Silencing of the novel p53 target gene Snk/Plk2 leads to mitotic catastrophe in paclitaxel (taxol)-exposed cells.

Authors:  Timothy F Burns; Peiwen Fei; Kimberly A Scata; David T Dicker; Wafik S El-Deiry
Journal:  Mol Cell Biol       Date:  2003-08       Impact factor: 4.272

8.  Senescing human cells and ageing mice accumulate DNA lesions with unrepairable double-strand breaks.

Authors:  Olga A Sedelnikova; Izumi Horikawa; Drazen B Zimonjic; Nicholas C Popescu; William M Bonner; J Carl Barrett
Journal:  Nat Cell Biol       Date:  2004-02       Impact factor: 28.824

9.  Targeted transgene insertion into human chromosomes by adeno-associated virus vectors.

Authors:  Roli Hirata; Joel Chamberlain; Rong Dong; David W Russell
Journal:  Nat Biotechnol       Date:  2002-07       Impact factor: 54.908

10.  B-Raf is dispensable for K-Ras-mediated oncogenesis in human cancer cells.

Authors:  Jung-Sik Kim; Carolyn Lee; Aaron Foxworth; Todd Waldman
Journal:  Cancer Res       Date:  2004-03-15       Impact factor: 12.701

View more
  84 in total

1.  Comparative genomic analysis of primary versus metastatic colorectal carcinomas.

Authors:  Efsevia Vakiani; Manickam Janakiraman; Ronglai Shen; Rileen Sinha; Zhaoshi Zeng; Jinru Shia; Andrea Cercek; Nancy Kemeny; Michael D'Angelica; Agnes Viale; Adriana Heguy; Philip Paty; Timothy A Chan; Leonard B Saltz; Martin Weiser; David B Solit
Journal:  J Clin Oncol       Date:  2012-06-04       Impact factor: 44.544

2.  PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor-positive breast cancer.

Authors:  Sherene Loi; Benjamin Haibe-Kains; Samira Majjaj; Francoise Lallemand; Virginie Durbecq; Denis Larsimont; Ana M Gonzalez-Angulo; Lajos Pusztai; W Fraser Symmans; Alberto Bardelli; Paul Ellis; Andrew N J Tutt; Cheryl E Gillett; Bryan T Hennessy; Gordon B Mills; Wayne A Phillips; Martine J Piccart; Terence P Speed; Grant A McArthur; Christos Sotiriou
Journal:  Proc Natl Acad Sci U S A       Date:  2010-05-17       Impact factor: 11.205

Review 3.  Oncogenic mutations of PIK3CA in human cancers.

Authors:  Yardena Samuels; Todd Waldman
Journal:  Curr Top Microbiol Immunol       Date:  2010       Impact factor: 4.291

Review 4.  Radiosensitization of prostate cancer by priming the wild-type p53-dependent cellular senescence pathway.

Authors:  Brian D Lehmann; James A McCubrey; David M Terrian
Journal:  Cancer Biol Ther       Date:  2007-08-05       Impact factor: 4.742

5.  Phase II study of panitumumab combined with capecitabine and oxaliplatin as first-line treatment in metastatic colorectal cancer patients: clinical results including extended tumor genotyping.

Authors:  George Papaxoinis; Vassiliki Kotoula; Eleni Giannoulatou; Georgia-Angeliki Koliou; Vasilios Karavasilis; Sotirios Lakis; Andreas Koureas; Mattheos Bobos; Elpida Chalaralambous; Emily Daskalaki; Kyriakos Chatzopoulos; George Tsironis; Elisavet Pazarli; Sofia Chrisafi; Epaminontas Samantas; Ioannis G Kaklamanos; Ioannis Varthalitis; Athina Konstantara; Konstantinos N Syrigos; George Pentheroudakis; Dimitrios Pectasides; George Fountzilas
Journal:  Med Oncol       Date:  2018-05-31       Impact factor: 3.064

6.  Mechanistic analysis of a DNA damage-induced, PTEN-dependent size checkpoint in human cells.

Authors:  Jung-Sik Kim; Xuehua Xu; Huifang Li; David Solomon; William S Lane; Tian Jin; Todd Waldman
Journal:  Mol Cell Biol       Date:  2011-05-02       Impact factor: 4.272

7.  Akt activation synergizes with Trp53 loss in oral epithelium to produce a novel mouse model for head and neck squamous cell carcinoma.

Authors:  Marta Moral; Carmen Segrelles; M Fernanda Lara; Ana Belén Martínez-Cruz; Corina Lorz; Mirentxu Santos; Ramón García-Escudero; Jerry Lu; Kaoru Kiguchi; Agueda Buitrago; Clotilde Costa; Cristina Saiz; Jose L Rodriguez-Peralto; Francisco J Martinez-Tello; Maria Rodriguez-Pinilla; Montserrat Sanchez-Cespedes; Marina Garín; Teresa Grande; Ana Bravo; John DiGiovanni; Jesús M Paramio
Journal:  Cancer Res       Date:  2009-01-27       Impact factor: 12.701

Review 8.  Prognostic and predictive biomarkers in metastatic colorectal cancer anti-EGFR therapy.

Authors:  Cristiana Lo Nigro; Vincenzo Ricci; Daniela Vivenza; Cristina Granetto; Teresa Fabozzi; Emanuela Miraglio; Marco C Merlano
Journal:  World J Gastroenterol       Date:  2016-08-14       Impact factor: 5.742

9.  PTEN-mediated ERK1/2 inhibition and paradoxical cellular proliferation following Pnck overexpression.

Authors:  Tushar B Deb; Robert J Barndt; Annie H Zuo; Surojeet Sengupta; Christine M Coticchia; Michael D Johnson
Journal:  Cell Cycle       Date:  2014-01-20       Impact factor: 4.534

10.  Increasing cisplatin sensitivity by schedule-dependent inhibition of AKT and Chk1.

Authors:  Lei Duan; Ricardo E Perez; Michael Hansen; Steven Gitelis; Carl G Maki
Journal:  Cancer Biol Ther       Date:  2014       Impact factor: 4.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.